Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

228.03 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >

5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗

March 09, 2024

Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...

Via Talk Markets

These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher ↗

March 03, 2024

Ethan Meyers, the research director at Westfield Capital Management, has a knack for identifying promising investments that have proven fruitful, especially for the Harbor Small Cap Growth Fund, where...

Via Benzinga

$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today ↗

February 23, 2024

Via Benzinga

How Is The Market Feeling About Ascendis Pharma? ↗

February 13, 2024

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today ↗

February 08, 2024

Via Benzinga

Earnings Scheduled For February 7, 2024 ↗

February 07, 2024

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.

Via Benzinga

Ascendis Pharma's Earnings: A Preview ↗

February 06, 2024

Via Benzinga

$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today ↗

February 02, 2024

Via Benzinga

Analyst Expectations for Ascendis Pharma's Future ↗

November 09, 2023

Via Benzinga

Recap: Ascendis Pharma Q3 Earnings ↗

November 07, 2023

Via Benzinga

Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial ↗

December 19, 2023

Ascendis Pharma A/S (NASDAQ: ASND) released topline results from Phase 3 foresiGHt trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth...

Via Benzinga

Preview: Ascendis Pharma's Earnings ↗

November 06, 2023

Via Benzinga

The Latest Analyst Ratings for Ascendis Pharma ↗

October 09, 2023

Via Benzinga

Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty ↗

September 28, 2023

Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in

Via Benzinga

The Latest Analyst Ratings for Ascendis Pharma ↗

September 07, 2023

Via Benzinga

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

September 05, 2023

From Royalty Pharma plc

Via GlobeNewswire

Earnings Preview For Ascendis Pharma ↗

September 04, 2023

Via Benzinga

Analyst Expectations for Ascendis Pharma's Future ↗

July 24, 2023

Via Benzinga

Where Ascendis Pharma Stands With Analysts ↗

June 20, 2023

Via Benzinga

The Latest Analyst Ratings for Ascendis Pharma ↗

June 01, 2023

Via Benzinga

Earnings Scheduled For September 5, 2023 ↗

September 05, 2023

Companies Reporting Before The Bell • Procaps Gr (NASDAQ:PROC) is likely to report earnings for its second quarter.

Via Benzinga

Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm

June 30, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm

June 25, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

FDA Rejects Ascendis Pharma's TransCon PTH For Hypoparathyroidism ↗

May 01, 2023

The FDA issued a complete response letter (CRL) for Ascendis Pharma A/S's

Via Benzinga

Why Shares of Ascendis Pharma Are Climbing Monday ↗

May 01, 2023

A critical response letter from the FDA means hope remains for the company's hyperthyroidism therapy candidate.

Via The Motley Fool

NASDAQ: ASND Investor Alert: Investigation over Potential Wrongdoing at Ascendis Pharma A/S ↗

June 20, 2023

San Diego, CA -- (SBWIRE) -- 06/20/2023 -- Certain directors of Ascendis Pharma A/S are under investigation over potential breaches of fiduciary duties by certain directors.

Via SBWire

Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm

June 19, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 01, 2023

Via Benzinga

US Stocks Rise; Norwegian Cruise Line Posts Q1 Results ↗

May 01, 2023

U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up...

Via Benzinga

IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

May 01, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Apollomics, Inc. (NASDAQ: APLM) surged 58.4% to $7.35 in pre-market trading...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.